<![CDATA[FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC]]>

Regulatoryzanzalintinib/atezolizumabNegative

AI Analysis

Summary

The FDA extended its review of zanzalintinib/atezolizumab for previously treated metastatic colorectal cancer, setting a new action date of March 3, 2027.

Outcome Details

FDA review extension with new action date set

Importance:6/10

Sentiment:

-0.30

FDAReview ExtensionColorectal CancerCombination TherapyRegulatory

Read the original article

Published by Cancer Network on September 14, 2026 2:00 PM

Read Original